; (2) provide an opportunity for public comment on such preliminary list; (3) not later than 1 year after such date of enactment, publish a final list of priority medicines; and (4) on an annual basis, review and, as appropriate, update such list. (e) Definitions In this section: (1) Active pharmaceutical ingredient The term active pharmaceutical ingredient — (A) means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of a disease, or to affect the structure or any function of the body of a human or animal; and (B) does not include— (i) intermediates used in the synthesis of a drug product; or (ii) components that may undergo chemical change in the manufacture of a drug product and be present in a drug product in a modified form that is intended to furnish such activity or effect. (2) Covered product The term covered product means a drug (including a biological product) or an active pharmaceutical ingredient. (3) Priority medicine The term priority medicine means a priority medicine for which a designation is in effect under subsection (a). . (b) National Strategic Health Strategy Section 2802(b) of the Public Health Service Act ( 42 U.S.C. 300hh–1(b) ) is amended by adding at the end the following: (11) Priority medicines Supporting the identification, production, and procurement of priority medicines designated under section 2804. . (c) Public Health Emergency Medical Countermeasures Enterprise recommendations Section 2811–1(c)(1) of the Public Health Service Act (42 U.S.C. 300hh–10a(c)) is amended by adding at the end the following: (E) Provide recommendations to the Secretary with respect to the priority medicines designated under section 2804. . (d) Strategic plan for countermeasure research, development, and procurement Section 319L(b) of the Public Health Service Act (42 U.S.C. 247d–7e(b)) is amended— (1) in paragraph (2)— (A) in subparagraph (B), by striking and at the end